Coagulation is a known contributor to cancer morbidity and mortality. In this study of oral squamous cell carcinoma (OSCC) cell lines, the authors describe a non-canonical form of platelet activation that is distinct from immediate responses to conventional agonists. Rather than prompting instantaneous platelet aggregation, OSCC-derived stimuli induce a delayed activation profile characterized by a time-dependent sequence of events culminating in de novo thrombin generation and PAR1-mediated platelet stimulation.
The platelet-activating activity from OSCC was not attributable to a soluble secreted factor. Instead, the activity was fully recovered in spontaneously shed extracellular vesicles (EVs) derived from OSCC cell lines. These EVs did not contain established platelet agonists, indicating that their stimulatory capacity operates by an alternative pathway that requires platelet interaction with the vesicle surface or vesicle-associated components rather than a classic soluble agonist binding event.
Biochemical and pharmacologic experiments described by the authors indicate that OSCC EVs foster assembly of the extrinsic and common coagulation complexes on quiescent platelets. This assembly proceeds to generate thrombin only after a significant delay. Newly formed thrombin acts on platelets through the canonical thrombin receptor PAR1, producing the platelet activation and aggregation responses observed. Thus, the EVs initiate a non-canonical, time-dependent pathway that converges on a canonical thrombin–PAR1 axis to produce platelet activation.
A critical, rate-limiting event in this sequence is the translocation of intracellular phosphatidylserine to the platelet outer membrane. The authors report that this phospholipid externalization is enabled by enzymatic oxidation of membrane lipids. The temporal delay in EV-induced platelet aggregation parallels the delayed appearance of phosphatidylserine on the platelet surface, linking membrane oxidation to the capacity of platelets to support coagulation complex assembly and subsequent thrombin production. In short, membrane phospholipid remodeling driven by oxidation is required before the platelet surface becomes a productive scaffold for coagulation factor binding and prothrombin activation.
Platelets were found to express the oxidant-generating (pro)renin receptor ((p)RR). Correspondingly, OSCC EVs contained prorenin, the physiological ligand for (p)RR. The (p)RR non-proteolytically activates prorenin, providing a mechanism by which EV-associated prorenin could trigger local oxidant generation on or within platelets. Interruption of this axis — either by using the decoy peptide PRO20 to block the prorenin–(p)RR interaction or by inhibiting renin enzymatic activity — suppressed both phosphatidylserine translocation and platelet activation in the experimental system, implicating prorenin/(p)RR signaling as a proximal mediator of the membrane oxidation required for coagulation complex formation.
Pharmacologic interventions reported in the work further clarify mechanistic steps. Blocking prorenin engagement of platelet (p)RR with PRO20 or inhibiting renin activity curtailed phosphatidylserine exposure and the ensuing platelet activation, supporting a functional role for the prorenin pathway. Separately, OSCC EVs produced delayed peroxidation of platelet membrane lipids; the intra-membranous radical trap Liproxstatin-1 prevented this phospholipid peroxidation, the surface display of phosphatidylserine, and platelet activation. These inhibitor data indicate that radical-mediated membrane oxidation is necessary for the EV-driven, time-dependent transition of platelets into a procoagulant state.
The authors conclude that the hysteresis — i.e., the delay — characteristic of this non-canonical, tumor cell-induced platelet activation represents a novel, time-dependent mechanism of prothrombin activation. The rate-limiting event is membrane oxidation that enables phosphatidylserine translocation to the platelet surface, which then permits assembly of coagulation complexes and generation of thrombin, the effective platelet agonist. The involvement of platelet (pro)renin receptor expression and prorenin contained in OSCC EVs provides a mechanistic link between tumor-derived vesicles and platelet oxidant pathways.
Limitations and details not reported
The abstract reports the key mechanistic findings and pharmacologic interventions but does not provide experimental details such as concentrations, time courses, quantitative measures of thrombin generation, or in vivo validation. Those specific methods and numerical outcomes were not reported in the abstract and would require consultation of the full article for precise experimental parameters and data.